JAK inhibitor Rinvoq treats endexual dermatitis: Phase III clinical efficacy is significant.

AbbVie's upadacitinib monotherapy reached its primary and secondary end point in the Measure Up 2 trial, the second Phase III study for patients with moderate to severe allergic dermatitis.
the main endpoints were a minimum of 75% higher eczema area severity index (EASI 75) than the baseline, and a 0/1 (clear or almost clear) special dermatitis (vIGA-AD) score for week 16 after the global assessment was validated.
Rinvoq is an oral, daily, selective and reversible JAK inhibitor approved in Europe for the treatment of patients with moderate to severe active rheumatoid arthritis who have a poor or insatiable response to one or more disease-relieving rheumatoids.
Photo Source: The results showed a significant increase in skin removal and itching reduction in patients treated with 15 mg/30 mg of Rinvoq at the 16th week compared to placebo, with 60% and 73% of patients reaching EASI 75, respectively, compared to 13% in the placebo group.
IGA-AD 0/1 were 39% and 52%, respectively, compared with 5% in the placebo group.
Severino, vice chairman and president of AbbVie, said: "We are encouraged by these results, which once again validate the Measure Up 1 data and highlight the potential therapeutic value of Rinvoq for patients with endexual dermatitis.
16 weeks, 42%/60% of patients treated with 15 mg/30 mg of Rinvoq showed a clinical reduction in itching, while 9% of patients received a placebo.
AbbVie also stressed that no new safety risks were found compared to patients treated with rheumatoid arthritis and psoriasis arthritis treated with Rinvoq.
.